Acute megakaryocytic leukemia: What have we learned

Andrew W. Hahn, Bojia Li, Philippe Prouet, Smith Giri, Ranjan Pathak, Michael Martin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Acute megakaryocytic leukemia (AMegL) is a biologically heterogenous subtype of acute myeloid leukemia (AML) that arises from megakaryocytes. Improvements in the accuracy of diagnosing AMegL as well as interest in the molecular analysis of leukemias have led to an increased amount of data available on this rare AML subtype. In this review, we will analyze the diverse molecular features unique to AMegL and how they have influenced the development of novel treatment strategies, including polyploidization. The review will also consider the data available on clinical outcomes in AMegL and how it is a poor individual prognostic factor for AML. Finally, the role of allogeneic hematopoietic stem cell transplant in AMegL will be explored.

Original languageEnglish (US)
Pages (from-to)49-53
Number of pages5
JournalBlood Reviews
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Leukemia, Megakaryoblastic, Acute
Acute Myeloid Leukemia
Megakaryocytes
Hematopoietic Stem Cells
Leukemia
Transplants

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Hahn, A. W., Li, B., Prouet, P., Giri, S., Pathak, R., & Martin, M. (2016). Acute megakaryocytic leukemia: What have we learned. Blood Reviews, 30(1), 49-53. https://doi.org/10.1016/j.blre.2015.07.005

Acute megakaryocytic leukemia : What have we learned. / Hahn, Andrew W.; Li, Bojia; Prouet, Philippe; Giri, Smith; Pathak, Ranjan; Martin, Michael.

In: Blood Reviews, Vol. 30, No. 1, 01.01.2016, p. 49-53.

Research output: Contribution to journalArticle

Hahn, AW, Li, B, Prouet, P, Giri, S, Pathak, R & Martin, M 2016, 'Acute megakaryocytic leukemia: What have we learned', Blood Reviews, vol. 30, no. 1, pp. 49-53. https://doi.org/10.1016/j.blre.2015.07.005
Hahn, Andrew W. ; Li, Bojia ; Prouet, Philippe ; Giri, Smith ; Pathak, Ranjan ; Martin, Michael. / Acute megakaryocytic leukemia : What have we learned. In: Blood Reviews. 2016 ; Vol. 30, No. 1. pp. 49-53.
@article{a99ca969c9e041629b5135b22b07c29f,
title = "Acute megakaryocytic leukemia: What have we learned",
abstract = "Acute megakaryocytic leukemia (AMegL) is a biologically heterogenous subtype of acute myeloid leukemia (AML) that arises from megakaryocytes. Improvements in the accuracy of diagnosing AMegL as well as interest in the molecular analysis of leukemias have led to an increased amount of data available on this rare AML subtype. In this review, we will analyze the diverse molecular features unique to AMegL and how they have influenced the development of novel treatment strategies, including polyploidization. The review will also consider the data available on clinical outcomes in AMegL and how it is a poor individual prognostic factor for AML. Finally, the role of allogeneic hematopoietic stem cell transplant in AMegL will be explored.",
author = "Hahn, {Andrew W.} and Bojia Li and Philippe Prouet and Smith Giri and Ranjan Pathak and Michael Martin",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.blre.2015.07.005",
language = "English (US)",
volume = "30",
pages = "49--53",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Acute megakaryocytic leukemia

T2 - What have we learned

AU - Hahn, Andrew W.

AU - Li, Bojia

AU - Prouet, Philippe

AU - Giri, Smith

AU - Pathak, Ranjan

AU - Martin, Michael

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Acute megakaryocytic leukemia (AMegL) is a biologically heterogenous subtype of acute myeloid leukemia (AML) that arises from megakaryocytes. Improvements in the accuracy of diagnosing AMegL as well as interest in the molecular analysis of leukemias have led to an increased amount of data available on this rare AML subtype. In this review, we will analyze the diverse molecular features unique to AMegL and how they have influenced the development of novel treatment strategies, including polyploidization. The review will also consider the data available on clinical outcomes in AMegL and how it is a poor individual prognostic factor for AML. Finally, the role of allogeneic hematopoietic stem cell transplant in AMegL will be explored.

AB - Acute megakaryocytic leukemia (AMegL) is a biologically heterogenous subtype of acute myeloid leukemia (AML) that arises from megakaryocytes. Improvements in the accuracy of diagnosing AMegL as well as interest in the molecular analysis of leukemias have led to an increased amount of data available on this rare AML subtype. In this review, we will analyze the diverse molecular features unique to AMegL and how they have influenced the development of novel treatment strategies, including polyploidization. The review will also consider the data available on clinical outcomes in AMegL and how it is a poor individual prognostic factor for AML. Finally, the role of allogeneic hematopoietic stem cell transplant in AMegL will be explored.

UR - http://www.scopus.com/inward/record.url?scp=84960298759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960298759&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2015.07.005

DO - 10.1016/j.blre.2015.07.005

M3 - Article

C2 - 26228843

AN - SCOPUS:84960298759

VL - 30

SP - 49

EP - 53

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 1

ER -